Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors.

In order to obtain information regarding the design of selective DPP4 inhibitors, a 3D-QSAR study was conducted using DPP4, DPP8, and DPP9 inhibitors including newly synthesized six- and seven-membered cyclic hydrazine derivatives (KR64300, KR64301), which were evaluated in vitro for their inhibition of DPP4, DPP8, and DPP9. In this study, a highly predictive CoMFA model based on the fast-docking for DPP4, DPP8, and DPP9 inhibitors was obtained. This reliable model showed leave-one-out cross-validation q(2) and conventional r(2) values of 0.68 and 0.96 for the DPP4 inhibitors, 0.58 and 0.98 for the DPP8 inhibitors, and 0.68 and 0.97 for the DPP9 inhibitors, respectively. The validation of the CoMFA model was confirmed by the compounds in the test set, including the synthesized six- and seven-membered cyclic hydrazines. According to this study, to obtain selective DPP4 inhibitors compared to their isozymes, the interaction of the inhibitors with the S3 site and S1' site in DPP4 must be considered. The proposed newly synthesized compounds, KR64300 and KR64301, interact well with the sites mentioned above, showing excellent selectivity.

[1]  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[2]  C. Abbott,et al.  Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. , 2004, Biochimica et biophysica acta.

[3]  J. Holst,et al.  Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. , 2000, European journal of pharmacology.

[4]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[5]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[6]  N. Thornberry,et al.  Dipeptidyl peptidase IV inhibitors derived from beta-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole. , 2005, Bioorganic & medicinal chemistry letters.

[7]  R. Pederson,et al.  Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. , 2002, Diabetes.

[8]  Gary M. Coppola,et al.  Chapter 19. DPP-IV inhibition and therapeutic potential , 2001 .

[9]  J. Holst,et al.  Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. , 2006, The international journal of biochemistry & cell biology.

[10]  E. Chiquette,et al.  Incretin Mimetics and Dipeptidyl Peptidase‐IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus , 2006, Pharmacotherapy.

[11]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[12]  G. Sutherland,et al.  Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. , 2000, European journal of biochemistry.

[13]  You-Jung Park,et al.  Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[14]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[15]  J. Kozarich,et al.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. , 2003, Current opinion in chemical biology.

[16]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[17]  Robert Huber,et al.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Joseph L Duffy,et al.  Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[19]  Jie-Oh Lee,et al.  Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[20]  Manuel C. Peitsch,et al.  Protein Modeling by E-mail , 1995, Bio/Technology.

[21]  Manuel C. Peitsch,et al.  SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..

[22]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.

[23]  I. Lu,et al.  Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[24]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[25]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[26]  T. Hughes,et al.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.

[27]  J. Peters,et al.  Inhibitors of dipeptidyl peptidase IV--recent advances and structural views. , 2005, Current topics in medicinal chemistry.

[28]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[29]  Walter Huber,et al.  Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. , 2003, Structure.